Gene therapy for B-cell lymphoma that hasn't responded to standard treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new gene therapy that re-engineers your own immune cells to attack CD19-positive lymphoma. It is for people whose B-cell lymphoma has come back or not responded to at least two standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell lymphoma (like DLBCL, follicular, or mantle cell) and have already tried at least two standard treatments that didn't work or stopped working.
- Your tumor cells tested positive for a marker called CD19.
- You have at least one measurable tumor (for example, a lymph node larger than 1.5 cm).
- Your liver, kidneys, and heart are working well enough (based on recent tests).
- You are not pregnant or breastfeeding, and you agree to use birth control for up to 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
This trial tests a new type of cell therapy—called CD19 CAR-γδT cells—for adults with B-cell lymphoma that has returned or not responded to standard treatments. The therapy uses your immune system's T cells, specially trained to find and attack cancer cells that carry the CD19 marker.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.